Roles of extracellular vesicles in pathogenesis and treatment of osteoporosis and their functionalized delivery strategies

doi:10.3969/j.issn.1674-8115.2026.09.003

Abstract

Abstract:

Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and disrupted bone microarchitecture, representing a major cause of disability and diminished quality of life among middle-aged and older adults while imposing a substantial socioeconomic burden worldwide. Extracellular vesicles (EVs) are membrane-bound nanoparticles that mediate intercellular communication by transferring proteins, lipids, and nucleic acids between cells. In the skeletal system, EVs participate in multiple stages of bone remodeling by promoting osteogenic differentiation, inhibiting osteoclast formation and function, and regulating angiogenesis, making them promising candidates for osteoporosis therapy. Nevertheless, the therapeutic application of native EVs is restricted by rapid clearance after administration and limited bone-targeting efficiency. Recent advances in EV engineering have provided new opportunities to address these limitations. This review summarizes the biological characteristics of EVs and discusses their regulatory roles in the bone microenvironment. It further focuses on emerging strategies for EV-based osteoporosis therapy, including donor-cell preconditioning to improve the biological activity of native EVs, cargo engineering and surface modification to enhance therapeutic efficacy and bone-targeting capability, and the combination of engineered EVs with biomaterial platforms such as hydrogels and three-dimensional printed scaffolds to construct delivery systems that enable localized retention, controlled release, and synergistic tissue repair. Finally, the current challenges associated with EV-based therapeutics and the prospects for their clinical translation are discussed. This review provides a theoretical basis and research perspective for the development of effective and safe cell-free bone regeneration therapies.

Key words: bone tissue engineering, extracellular vesicle (EV), osteoporosis, bone regeneration

CLC Number:

R318

Zhang Xin, Li Dan, Yang Ju, Deng Kelei, Cao Hong. Roles of extracellular vesicles in pathogenesis and treatment of osteoporosis and their functionalized delivery strategies[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026,(9): 1179-1187.

Figures/Tables 1

TrendMD

References 62

[1]	周云帆, 童铭豪, 张伟刚, 等. 芹菜素调控骨代谢治疗骨质疏松症的研究进展[J]. 现代药物与临床, 2025, 40(10): 2655-2659.
	Zhou Y F, Tong M H, Zhang W G, et al. Research progress on apigenin in regulating bone metabolism for the treatment of osteoporosis[J]. Modern Drugs and Clinical, 2025, 40(10): 2655-2659.
[2]	Williams S A, Daigle S G, Weiss R, et al. Economic burden of osteoporosis-related fractures in the US medicare population[J]. Ann Pharmacother, 2021, 55(7): 821-829.
[3]	Wang L J, You X L, Zhang L L, et al. Mechanical regulation of bone remodeling[J]. Bone Res, 2022, 10(1): 16.
[4]	姚玉红, 何姣, 单琳, 等. 老年骨质疏松症患者双膦酸盐类药物治疗用药依从性研究进展[J]. 护理与康复, 2024, 23(7): 94-98.
	Yao Y H, He J, Shan L, et al. Research progress on medication adherence to bisphosphonate therapy in elderly patients with osteoporosis [J]. Nursing and Rehabilitation, 2024, 23(7): 94-98.
[5]	王瑞. 选择性雌激素受体调节剂治疗绝经后女性骨质疏松症的效果及骨代谢指标研究[J]. 医学理论与实践, 2025, 38(15): 2603-2605.
	Wang R. Effects of selective estrogen receptor modulators in the treatment of postmenopausal osteoporosis and related bone metabolism indicators [J]. Medical Theory and Practice, 2025, 38(15): 2603-2605.
[6]	姚娟娟, 石春霞, 张乐媛, 等. 甲状旁腺激素类似物与双膦酸盐序贯治疗骨质疏松症有效性与安全性的Meta分析[J]. 中国药房, 2024, 35(24): 3059-3064.
	Yao J J, Shi C X, Zhang L Y, et al. Efficacy and safety of sequential therapy with parathyroid hormone analogs and bisphosphonates for osteoporosis: a meta-analysis [J]. China Pharmacy, 2024, 35(24): 3059-3064.
[7]	Leder B Z, Tsai J N, Uihlein A V, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial[J]. Lancet, 2015, 386(9999): 1147-1155.
[8]	柳忠豪, 董凯. 骨质疏松症患者口腔种植治疗的风险与对策[J]. 中国口腔种植学杂志, 2024, 29(4): 303-310.
	Liu Z H, Dong K. Risks and countermeasures of oral implant therapy in patients with osteoporosis [J]. Chinese Journal of Oral Implantology, 2024, 29(4): 303-310.
[9]	张格, 朱涵, 张婧雯, 等. 诱导胚胎干细胞分化为视网膜色素上皮细胞的培养方法[J]. 国际眼科杂志, 2020, 20(12): 2079-2082.
	Zhang G, Zhu H, Zhang J W, et al. Culture methods for inducing embryonic stem cells to differentiate into retinal pigment epithelial cells [J]. International Journal of Ophthalmology, 2020, 20(12): 2079-2082.
[10]	Matsuzaka Y, Yashiro R. Therapeutic strategy of mesenchymal-stem-cell-derived extracellular vesicles as regenerative medicine[J]. Int J Mol Sci, 2022, 23(12): 6480.
[11]	van Griensven M, Balmayor E R. Extracellular vesicles are key players in mesenchymal stem cells' dual potential to regenerate and modulate the immune system[J]. Adv Drug Deliv Rev, 2024, 207: 115203.
[12]	Karoichan A, Li L, Agnes C J, et al. Mesenchymal stem cells-derived extracellular vesicles mimetics as osteoinductive mediators for bone healing[J]. Adv Funct Mater, 2025, 35(29): 2419562.
[13]	Tartaglia N R, Martin-Jaular L, Joliot A, et al. Extracellular vesicles: a complex array of particles involved in cell-to-cell communication for tissue homeostasis[J]. Cells Dev, 2026, 185: 204054.
[14]	Xiang H Y, Bao C X, Chen Q Q, et al. Extracellular vesicles (EVs)′ journey in recipient cells: from recognition to cargo release[J]. J Zhejiang Univ Sci B, 2024, 25(8): 633-655.
[15]	Manai F, Smedowski A, Kaarniranta K, et al. Extracellular vesicles in degenerative retinal diseases: a new therapeutic paradigm[J]. J Control Release, 2024, 365: 448-468.
[16]	Chen H Y, Sun T, Jiang C. Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy[J]. J Control Release, 2022, 348: 572-589.
[17]	Padinharayil H, Varghese J, Wilson C, et al. Mesenchymal stem cell-derived exosomes: characteristics and applications in disease pathology and management[J]. Life Sci, 2024, 342: 122542.
[18]	Zhu S L, Li S Y, Yi M, et al. Roles of microvesicles in tumor progression and clinical applications[J]. Int J Nanomed, 2021, 16: 7071-7090.
[19]	Song S S, Guo Y Y, Yang Y H, et al. Advances in pathogenesis and therapeutic strategies for osteoporosis[J]. Pharmacol Ther, 2022, 237: 108168.
[20]	Batsali A K, Georgopoulou A, Mavroudi I, et al. The role of bone marrow mesenchymal stem cell derived extracellular vesicles (MSC-EVs) in normal and abnormal hematopoiesis and their therapeutic potential[J]. J Clin Med, 2020, 9(3): 856.
[21]	Luo K Y, Jin Y F, Liu B Y, et al. Harnessing bone marrow mesenchymal stem cell-derived extracellular vesicles and biomimetic peptide WKYMVm in self-healing hydrogel for enhanced bone repair in femoral defects[J]. J Tissue Eng, 2024, 15: 20417314241306681.
[22]	Zou J X, Yang W N, Cui W S, et al. Therapeutic potential and mechanisms of mesenchymal stem cell-derived exosomes as bioactive materials in tendon-bone healing[J]. J Nanobiotechnology, 2023, 21(1): 14.
[23]	Chen B K, Zhang Y X, Liu O S. microRNAs in maxillofacial bone modeling and remodeling: implications for malocclusion development and orthodontic treatment[J]. Front Cell Dev Biol, 2024, 12: 1355312.
[24]	Las Heras K, Garcia-Orue I, Rancan F, et al. Modulating the immune system towards a functional chronic wound healing: a biomaterials and Nanomedicine perspective[J]. Adv Drug Deliv Rev, 2024, 210: 115342.
[25]	Nakao Y, Fukuda T, Zhang Q Z, et al. Exosomes from TNF-α-treated human gingiva-derived MSCs enhance M2 macrophage polarization and inhibit periodontal bone loss[J]. Acta Biomater, 2021, 122: 306-324.
[26]	Longo A, Manganelli V, Misasi R, et al. Extracellular vesicles in the crosstalk of autophagy and apoptosis: a role for lipid rafts[J]. Cells, 2025, 14(10): 749.
[27]	Cheng P Z, Cao T Q, Zhao X Y, et al. Nidogen1-enriched extracellular vesicles accelerate angiogenesis and bone regeneration by targeting Myosin-10 to regulate endothelial cell adhesion[J]. Bioact Mater, 2022, 12: 185-197.
[28]	Liam-Or R, Faruqu F N, Walters A, et al. Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent[J]. Nat Nanotechnol, 2024, 19(6): 846-855.
[29]	Liu N, Ma Y Z, Gong W, et al. Osteocyte-derived extracellular vesicles mediate the bone-to-cartilage crosstalk and promote osteoarthritis progression[J]. Nat Commun, 2025, 16(1): 4746.
[30]	Dave K M, Pinky P P, S Manickam D. Molecular engineering of extracellular vesicles for drug delivery: strategies, challenges, and perspectives[J]. J Control Release, 2025, 386: 114068.
[31]	Duan J X, Li H, Wang C Y, et al. BMSC-derived extracellular vesicles promoted osteogenesis via Axin2 inhibition by delivering miR-16-5p[J]. Int Immunopharmacol, 2023, 120: 110319.
[32]	Liu Y, Sun L, Li Y, et al. Mesenchymal stromal/stem cell tissue source and in vitro expansion impact extracellular vesicle protein and miRNA compositions as well as angiogenic and immunomodulatory capacities[J]. J Extracell Vesicles, 2024, 13(8): e12472.
[33]	Shahid H, Morya V K, Oh J U, et al. Hypoxia-inducible factor and oxidative stress in tendon degeneration: a molecular perspective[J]. Antioxidants (Basel), 2024, 13(1): 86.
[34]	Tan Y L, Al-Masawa M E, Eng S P, et al. Therapeutic efficacy of interferon-gamma and hypoxia-primed mesenchymal stromal cells and their extracellular vesicles: underlying mechanisms and potentials in clinical translation[J]. Biomedicines, 2024, 12(6): 1369.
[35]	Terriaca S, Fiorelli E, Scioli M G, et al. Endothelial progenitor cell-derived extracellular vesicles: potential therapeutic application in tissue repair and regeneration[J]. Int J Mol Sci, 2021, 22(12): 6375.
[36]	Eichholz K F, Woods I, Riffault M, et al. Human bone marrow stem/stromal cell osteogenesis is regulated via mechanically activated osteocyte-derived extracellular vesicles[J]. Stem Cells Transl Med, 2020, 9(11): 1431-1447.
[37]	Zuppone S, Zarovni N, Noguchi K, et al. Novel loading protocol combines highly efficient encapsulation of exogenous therapeutic toxin with preservation of extracellular vesicles properties, uptake and cargo activity[J]. Discov Nano, 2024, 19(1): 76.
[38]	Cao Z L, Wu Y F, Yu L L, et al. Exosomal miR-335 derived from mature dendritic cells enhanced mesenchymal stem cell-mediated bone regeneration of bone defects in athymic rats[J]. Mol Med, 2021, 27(1): 20.
[39]	Hu H F, Wang D, Li L H, et al. Role of microRNA-335 carried by bone marrow mesenchymal stem cells-derived extracellular vesicles in bone fracture recovery[J]. Cell Death Dis, 2021, 12(2): 156.
[40]	Tang J D, Wang X Y, Lin X, et al. Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases[J]. Cell Death Discov, 2024, 10(1): 212.
[41]	Venslauskas M S, Šatkauskas S. Mechanisms of transfer of bioactive molecules through the cell membrane by electroporation[J]. Eur Biophys J, 2015, 44(5): 277-289.
[42]	Li S, Li W Q, Wu X G, et al. Immune cell-derived extracellular vesicles for precision therapy of inflammatory-related diseases[J]. J Control Release, 2024, 368: 533-547.
[43]	Zhao S, Di Y F, Fan H L, et al. Targeted delivery of extracellular vesicles: the mechanisms, techniques and therapeutic applications[J]. Mol Biomed, 2024, 5(1): 60.
[44]	Liu H M, Li M T, Xiang B, et al. An integrated “Engage & Evasion” approach for mononuclear phagocyte system escape and efficient extracellular vesicle therapy[J]. J Nanobiotechnol, 2024, 22(1): 770.
[45]	Hao Y, Zhou X X, Li Y L, et al. The CD47-SIRPα axis is a promising target for cancer immunotherapies[J]. Int Immunopharmacol, 2023, 120: 110255.
[46]	Adelnia H, Sirous F, Blakey I, et al. Metal ion chelation of poly(aspartic acid): from scale inhibition to therapeutic potentials[J]. Int J Biol Macromol, 2023, 229: 974-993.
[47]	Liu Q S, Li D F, Pan X H, et al. Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification[J]. J Nanobiotechnology, 2023, 21(1): 334.
[48]	Murali V P, Holmes C A. Biomaterial-based extracellular vesicle delivery for therapeutic applications[J]. Acta Biomater, 2021, 124: 88-107.
[49]	Peng Z Y, Wang C Q, Liu C, et al. 3D printed polycaprolactone/beta-tricalcium phosphate/magnesium peroxide oxygen releasing scaffold enhances osteogenesis and implanted BMSCs survival in repairing the large bone defect[J]. J Mater Chem B, 2021, 9(28): 5698-5710.
[50]	Uman S, Weingarten N, Helmers M, et al. Engineering and monitoring the sustained release of extracellular vesicles from hydrogels for in vivo therapeutic applications[J]. Adv Nanobiomed Res, 2024, 4(11): 2400073.
[51]	Anggelia M R, Cheng H Y, Lin C H. Thermosensitive hydrogels as targeted and controlled drug delivery systems: potential applications in transplantation[J]. Macromol Biosci, 2024: 2400064.
[52]	Liu S C, Wang Z R, Li Y H, et al. Erythropoietin-stimulated macrophage-derived extracellular vesicles in chitosan hydrogel rescue BMSCs fate by targeting EGFR to alleviate inflammatory bone loss in periodontitis[J]. Adv Sci (Weinh), 2025, 12(23): e2500554.
[53]	Lu W, Zeng M, Liu W B, et al. Human urine-derived stem cell exosomes delivered via injectable GelMA templated hydrogel accelerate bone regeneration[J]. Mater Today Bio, 2023, 19: 100569.
[54]	Zhou Y J, Liu S Y, Zhao M, et al. Injectable extracellular vesicle-released self-assembling peptide nanofiber hydrogel as an enhanced cell-free therapy for tissue regeneration[J]. J Control Release, 2019, 316: 93-104.
[55]	Lin C, He J L, Li J C, et al. Metal coordination-based double-network microsphere scaffolds facilitate bone regeneration via oxygen-driven mitochondrial oxidative phosphorylation[J]. Chem Eng J, 2025, 512: 162233.
[56]	Qin T W, Lian X J, Ullah A, et al. The multi-scale porous and hydrophilic 3D printed polycaprolactone/silk fibroin/β-tricalcium phosphate bone scaffolds effect on femoral defect repair[J]. Int J Biol Macromol, 2025, 330(Pt 4): 148230.
[57]	Hariprasad B, Eslamian M, Patel N, et al. A process optimization and release modeling of coaxial electrospun aligned core-shell poly (ethylene oxide-poly(l-lactide-co-glycolide)) nanofibers encapsulating nerve growth factor[J]. J Appl Polym Sci, 2025, 142(32): 57292.
[58]	Cai Y J, Zhang H J, Fan X N, et al. Hit the bull's eye: engineered extracellular vesicles for targeted therapy[J]. Bioact Mater, 2026, 64: 324-358.
[59]	Wang D R, Pan J. Extracellular vesicles: emerged as a promising strategy for regenerative medicine[J]. World J Stem Cells, 2023, 15(4): 165-181.
[60]	Xu G L, Jin J, Fu Z H, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies[J]. Signal Transduct Target Ther, 2025, 10(1): 255.
[61]	Jin S L, Lv Z Y, Kang L, et al. Next generation of neurological therapeutics: native and bioengineered extracellular vesicles derived from stem cells[J]. Asian J Pharm Sci, 2022, 17(6): 779-797.
[62]	Carney R P, Mizenko R R, Bozkurt B T, et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications[J]. Nat Nanotechnol, 2025, 20(1): 14-25.